Atherosclerosis vaccine - AFFiRiS

Drug Profile

Atherosclerosis vaccine - AFFiRiS

Alternative Names: ATH-03

Latest Information Update: 13 Jul 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator AFFiRiS
  • Class Antihyperlipidaemics; Protein-vaccines; Vaccines
  • Mechanism of Action Cholesterol ester transfer protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Atherosclerosis

Most Recent Events

  • 12 Jul 2012 Affiris completes a phase I trial in Healthy volunteers in Austria (NCT01284582)
  • 03 Nov 2011 Affiris completes enrolment in its phase I trial for Atherosclerosis in Austria (NCT01284582)
  • 19 May 2011 Phase-I clinical trials in Atherosclerosis in Austria (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top